Related Experiment Videos
The role of sequential chemoradiation for local advanced oropharyngeal carcinoma
1Department of ENT, Cambridge University Hospitals Trust, Hills Road, Cambridge, CB2 0QQ, UK, lmm398@doctors.org.uk.
Background:
This study aims to assess survival, prognostic indicators, and pattern of failure for advanced oropharyngeal cancer treated by induction chemotherapy followed by concomitant chemoradiation (sequential CRT).
Methods:
A retrospective review of 80 consecutive patients who underwent chemoradiation [doublet cisplatin and 5-fluorouracil (PF)] for local advanced oropharyngeal carcinoma at a tertiary center from March 2003 to July 2008 is reported. Seven studies utilizing a similar protocol were reviewed, and all outcomes are collated.
Result:
At a median follow-up of 32 months, the 3-year overall survival was 75%. Tumor size (p < 0.001), age at presentation (p < 0.002), and failure to complete the full course of induction chemotherapy (p < 0.01) were all found to be significant factors affecting survival.
Conclusion:
Induction chemotherapy followed by concomitant chemoradiation utilizing doublet PF is an effective treatment for local advanced oropharyngeal carcinoma. At present, the addition of a taxane to the PF regimen cannot be assumed to provide benefit until further evidence emerges from a representative controlled trial.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Treatment Resistent Cancers
Treatment Resistant Cancers